Receiving brentuximab vedotin injection may increase the risk that you will develop progressive multifocal leukoencephalopathy (PML; a rare infection of the brain that cannot be treated, prevented, or cured and that usually causes death or severe disability). Tell your doctor if you have or have ever had a condition that affects your immune system. Tell your doctor and pharmacist if you are taking any medications that suppress the immune system. If you experience any of the following symptoms, stop receiving brentuximab vedotin injection and call your doctor immediately: decreased strength or weakness on one side of the body; difficulty walking; loss of coordination; headache; confusion; difficulty thinking clearly; memory loss; changes in mood or usual behavior; difficulty speaking; or vision problems.
Keep all appointments with your doctor and the laboratory. Your doctor may order certain tests to check your body's response to brentuximab vedotin injection.
Talk to your doctor about the risks of receiving brentuximab vedotin injection.
Brentuximab vedotin injection is used to treat patients with Hodgkin's lymphoma who did not respond to a stem cell transplant (procedure that replaces diseased bone marrow with healthy bone marrow) or at least two treatment periods of chemotherapy. Brentuximab vedotin injection is also used to treat systemic anaplastic large cell lymphoma (sALCL; a type of non-Hodgkin lymphoma) who did not respond to another treatment period of chemotherapy. Brentuximab vedotin injection is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.
Brentuximab vedotin injection comes as a powder to be mixed with fluid and injected over 30 minutes intravenously (into a vein) by a doctor or nurse in a medical office or hospital. It is usually injected once every 3 weeks. This treatment period is called a cycle, and the cycle may be repeated up to 16 times.
Brentuximab vedotin injection may cause serious allergic reactions, which usually occur during the infusion of the medication or within 24 hours of receiving a dose. You may receive certain medications before your infusion to prevent an allergic reaction if you had a reaction with previous treatment. Your doctor will watch you carefully while you are receiving brentuximab vedotin. If you experience any of the following symptoms, tell your doctor immediately: fever, chills, rash, hives, itching, or difficulty breathing.
Your doctor may need to delay your treatment, adjust your dose, or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with brentuximab vedotin injection.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Before receiving brentuximab vedotin injection,
- tell your doctor and pharmacist if you are allergic to brentuximab vedotin, any other medications, or any of the ingredients in brentuximab vedotin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor if you are receiving bleomycin (Blenoxane). Your doctor will probably tell you not to use brentuximab vedotin injection if you are receiving this medication.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole (Nizoral), nefazodone, nelfinavir (Viracept), rifampin (Rifadin, in Rifamate, in Rifater, Rimactane), and ritonavir (Norvir, in Kaletra). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while receiving brentuximab vedotin injection, call your doctor. Brentuximab vedotin injection may harm the fetus.
Unless your doctor tells you otherwise, continue your normal diet.
Brentuximab vedotin injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- stomach pain
- decreased appetite
- weight loss
- difficulty falling asleep or staying asleep
- hair loss
- night sweats
- joint, muscle, back, arm, or leg pain
- muscle spasms
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:
- unusual bleeding or bruising
- numbness, burning, or tingling in the hands, arms, feet, or legs
- muscle weakness
- peeling or blistering skin
- decreased urination
- swelling of the hands, feet, ankles, or lower legs
- difficult, painful, or frequent urination
- fever, chills, cough, or other signs of infection
Brentuximab vedotin injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at Web Site] or by phone [1-800-332-1088].
In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.
Symptoms of overdose may include the following:
- fever, chills, cough, or other signs of infection
Ask your pharmacist any questions you have about brentuximab vedotin injection.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: March 15, 2012.